FindTrial
Sign In

The Big Lung Trial: Does Short-Term Chemotherapy Improve the Survival of Patients with Non-Small Cell Lung Cancer (NSCLC)

The Big Lung Trial: Does Short-Term Chemotherapy Improve the Survival of Patients with Non-Small Cell Lung Cancer (NSCLC)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN57155593
Enrollment
Unknown
Registered
2002-08-19
Start date
1995-01-01
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung (non-small cell) Cancer Lung (non-small cell)

Interventions

1. CHEMOTHERAPY REGIMEN: Three cycles of one of the following regimens should be given: Cisplatin plus vindesine
Mitomycin C, ifosfamide and cisplatin
Mitomycin C, vinblastine and cisplatin
Navelbine and Cisplatin. Chemotherapy may be given as follows: A. Adjuvant Chemotherapy Option: Chemotherapy to start as soon as possible after surgery or following completion of radical radiothera

Sponsors

NHS R&D 'Time-Limited' National Programmes
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Fulfil local criteria for diagnosis of NSCLC 2. Be fit to receive, and have no clear contraindications to chemotherapy 3. Patients randomised to adjuvant chemotherapy should be able to start chemotherapy within 10 weeks of completion of surgery or radical radiotherapy 4. No concurrent malignancy, or any history of malignancy, other than non-melanomatous skin cancer within the last 3 years

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026